A new paper published in the journal mAbs describes how researchers at the Institute for Bioscience and Biotechnology Research (IBBR), a joint institute of NIST and the University of Maryland have engineered three mouse cell lines to produce nonproprietary versions of NISTmAb that closely resemble the characteristics of the original reference material. This discovery is an important step in improving the manufacturing process of biologic drugs used to fight health conditions such as cancer, autoimmune disorders, and infectious diseases.
Read the full story via NIST.